Top Page
Beijing Tong Ren Tang Chinese Medicine Co
(OTC:3613)
Beijing Tong Ren Tang Chinese Medicine Co (3613) vs. iShares MSCI Hong Kong ETF (EWH)
Beijing Tong Ren Tang Chinese Medicine Co Business Overview & Revenue Model
Beijing Tong Ren Tang Chinese Medicine Co Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.61B | 1.52B | 1.73B | 1.56B | 1.32B | Gross Profit |
| 1.07B | 1.05B | 1.15B | 1.12B | 952.90M | EBIT |
| 576.92M | 624.15M | 811.58M | 778.46M | 669.40M | EBITDA |
| 722.32M | 779.54M | 907.63M | 852.81M | 769.14M | Net Income Common Stockholders |
| 500.28M | 540.39M | 645.88M | 607.84M | 542.46M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.82B | 2.38B | 2.24B | 2.28B | 1.85B | Total Assets |
| 4.56B | 4.43B | 4.23B | 3.83B | 3.42B | Total Debt |
| 123.42M | 131.81M | 103.08M | 128.48M | 106.01M | Net Debt |
| -1.65B | -868.00M | -1.89B | -1.53B | -1.32B | Total Liabilities |
| 313.09M | 413.75M | 486.49M | 295.48M | 287.46M | Stockholders Equity |
| 4.08B | 3.87B | 3.60B | 3.42B | 3.02B |
| Cash Flow | Free Cash Flow | |||
| 0.00 | 438.96M | 508.94M | 753.74M | 103.17M | Operating Cash Flow |
| 0.00 | 460.83M | 547.44M | 777.17M | 116.05M | Investing Cash Flow |
| 1.31B | -1.08B | 335.41M | -265.73M | 506.73M | Financing Cash Flow |
| 0.00 | -372.18M | -535.42M | -278.65M | -264.30M |
Beijing Tong Ren Tang Chinese Medicine Co Technical Analysis
Beijing Tong Ren Tang Chinese Medicine Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | 2.25 | ― | ― | ― | |||
76 Outperform | $104.07B | 22.11 | 13.20% | 2.21% | -9.60% | -27.18% | |
75 Outperform | HK$6.05B | 6.61 | 11.61% | 9.61% | -18.09% | -15.08% | |
74 Outperform | HK$112.91B | 31.58 | 8.17% | ― | 7.52% | -1.92% | |
68 Neutral | HK$7.35B | 14.51 | 12.58% | 6.90% | 5.69% | -7.43% | |
62 Neutral | HK$33.67B | 9.16 | 3.05% | ― | ― | ||
54 Neutral | $5.41B | 3.27 | -45.10% | 3.29% | 16.81% | 0.02% |
Beijing Tong Ren Tang Chinese Medicine Co Corporate Events
Beijing Tong Ren Tang Chinese Medicine Co. has announced the postponement and rescheduling of its Annual General Meeting (AGM) to June 3, 2025, to allow more time for preparations. Consequently, the book closure periods for determining shareholder entitlements to attend the AGM and receive the final dividend for 2024 have been adjusted, impacting shareholders’ timelines for registration and dividend receipt.
Beijing Tong Ren Tang Chinese Medicine Co announced a postponement and rescheduling of its annual general meeting, which is set to approve a final dividend of HKD 0.35 per share for the year ended December 31, 2024. This update affects the book closure dates for determining dividend entitlement, with the new record date set for June 11, 2025, and payment scheduled for June 18, 2025. This announcement may impact shareholder expectations and the company’s financial planning.
Beijing Tong Ren Tang Chinese Medicine Company Limited has announced its Annual General Meeting scheduled for June 3, 2025, where key resolutions will be discussed. These include the adoption of financial statements, re-election of directors, approval of a final dividend of HK$0.35 per share, and the re-appointment of Ernst & Young as auditors. The meeting will also address the authorization for directors to manage share-related transactions, potentially impacting the company’s market operations and shareholder value.
Beijing Tong Ren Tang Chinese Medicine Co. announced the release of unaudited financial information for the first quarter of 2025 by its controlling shareholder, Tong Ren Tang Technologies Co. Ltd. This announcement is significant as it provides stakeholders with an early insight into the financial performance of the company and its subsidiaries, potentially impacting investor decisions and market positioning within the traditional Chinese medicine sector.
Beijing Tong Ren Tang Chinese Medicine Co. has entered into a strategic cooperation agreement with China Duty Free International Limited. This partnership aims to leverage both companies’ strengths to expand overseas markets, particularly in the Belt and Road and Southeast Asia regions. The collaboration will focus on expanding cooperation channels, developing exclusive product versions, and exploring innovative business models in Chinese health food and beverage. The agreement is effective for two years, with mechanisms for regular communication and coordination to ensure successful implementation.
Beijing Tong Ren Tang Chinese Medicine Co. reported its annual financial results for the year ending December 31, 2024. The company experienced a 5.7% increase in revenue to HK$1,611,644,000, but saw a decrease in profit for the year by 10.4% to HK$529,167,000. Despite the decline in profit, the company proposed a higher final dividend per share, indicating a commitment to returning value to shareholders. The results reflect challenges in managing costs and maintaining profitability amidst increased inventories and reduced cash balances.
Beijing Tong Ren Tang Chinese Medicine Co announced a final cash dividend of HKD 0.35 per share for the year ended December 31, 2024. The dividend will be paid on June 13, 2025, following shareholder approval on May 28, 2025. This announcement reflects the company’s stable financial performance and commitment to returning value to its shareholders, potentially strengthening its market position and investor confidence.
The company has established a Nomination Committee to oversee the structure, size, and composition of its Board of Directors. This move is aimed at ensuring the board’s alignment with the company’s corporate strategy and enhancing governance by assessing the independence of its directors and recommending qualified individuals for directorships.
Beijing Tong Ren Tang Chinese Medicine Co has announced the appointment of Ms. Feng Li as a member of its nomination committee, effective from March 28, 2025. This strategic appointment is expected to enhance the governance structure of the company, potentially impacting its decision-making processes and industry positioning.
The company has announced the composition of its board of directors and their roles, highlighting the leadership structure with Gu Hai Ou as Chairman and Wang Chi as CEO. This announcement provides clarity on the governance framework, which could impact the company’s strategic direction and reassure stakeholders about its management stability.
Beijing Tong Ren Tang Chinese Medicine Co announced the forfeiture of unclaimed dividends declared on 12 March 2018, which will revert to the company if not claimed by 30 April 2025. This move highlights the company’s adherence to its Articles of Association and may impact shareholders who have not yet claimed their dividends.
Beijing Tong Ren Tang Chinese Medicine Co. announced that its board of directors will meet on March 28, 2025, to approve the annual results for 2024 and consider the payment of a final dividend. This meeting could impact the company’s financial strategy and stakeholder returns, reflecting its ongoing commitment to transparency and shareholder value.